Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Faiez ZannadStefan D AnkerWilliam M ByraJohn G F ClelandMin FuMihai GheorghiadeCarolyn S P LamMandeep R MehraJames D NeatonChristopher C NesselTheodore E SpiroDirk J van VeldhuisenBarry Greenbergnull nullPublished in: The New England journal of medicine (2018)
Rivaroxaban at a dose of 2.5 mg twice daily was not associated with a significantly lower rate of death, myocardial infarction, or stroke than placebo among patients with worsening chronic heart failure, reduced left ventricular ejection fraction, coronary artery disease, and no atrial fibrillation. (Funded by Janssen Research and Development; COMMANDER HF ClinicalTrials.gov number, NCT01877915 .).
Keyphrases
- atrial fibrillation
- ejection fraction
- aortic stenosis
- coronary artery disease
- left ventricular
- heart failure
- left atrial
- oral anticoagulants
- percutaneous coronary intervention
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- cardiovascular events
- coronary artery bypass grafting
- physical activity
- hypertrophic cardiomyopathy
- acute heart failure
- acute myocardial infarction
- coronary artery
- mitral valve
- double blind
- cardiac resynchronization therapy
- phase iii
- aortic valve
- transcatheter aortic valve replacement
- pulmonary embolism
- blood brain barrier